Eliem Therapeutics emerged from stealth mode with $80 million in financing that will be used to develop therapeutics aimed at treating neuronal excitability disorders such as chronic pain, depression, epilepsy and anxiety.
The disorders Eliem is targeting have a wide patient population across the globe. Seattle-based Eliem, which was officially founded in 2019 by RA Capital Management, is advancing two clinical-stage assets for neurological diseases. ETX-810, an investigational new chemical entity for chronic pain, acts via the palmitoylethanolamide (PEA) pathway. It is being evaluated in two Phase IIa trials in lumbosacral radicular pain (chronic sciatica) and diabetic peripheral neuropathic pain.
